Currently, several antibodies have been marketed (e.g., nivolumab and pembrolizumab against PD-1; atezolizumab and avelumab against PD-L1), and antibodies against the PD-1 pathway are revolutionizing cancer immunotherapy30,31. This evidence concerns the gene CD274 and cancer.